Company

BeyondSpring Inc.

Headquarters: New York, NY, United States

Employees: 91

CEO: Dr. Lan Huang

NASDAQ: BYSI +1.75%

Market Cap

$36.2 Million

USD as of Jan. 1, 2024

Market Cap History

BeyondSpring Inc. market capitalization over time

Evolution of BeyondSpring Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of BeyondSpring Inc.

Detailed Description

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and developing Plinabulin, which is in Phase III clinical trial for the treatment of later-stage non-small cell lung cancer (NSCLC). It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

BeyondSpring Inc. has the following listings and related stock indices.


Stock: NASDAQ: BYSI wb_incandescent

Details

Headquarters:

28 Liberty Street

39th Floor

New York, NY 10005

United States

Phone: 646 305 6387

Fax: 646 219 9660